| Covenant Hospice Care Llc 2630 West Freeway Suite 130, Fort Worth, TX, 76102 | |
| (972) 548-1600 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Cigarette smoking is associated with frequent substance use and poor behavioral and physical health in sexual and gender minority populations, according to Rutgers researchers.
The majority of hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project improve surgical outcomes over time, and improvement continues with each year that hospitals participate in the program, according to a new study published online today in Annals of Surgery.
Grégoire Courtine doesn't hesitate to use the word "revolutionary" when describing the emerging field of optogenetics – a technology that uses pulses of light to control individual neural activity – and what it could mean for neuroscience. Courtine, director of the NeuroRestore research center (with neurosurgeon Jocelyne Bloch), is currently developing an optogenetic implant together with Stéphanie Lacour, who holds the Bertarelli Foundation Chair in Neuroprosthetic Technology.
In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.
› Verified 8 days ago
| Name | Covenant Hospice Care Llc |
|---|---|
| Location | 2630 West Freeway Suite 130, Fort Worth, Texas |
| Hospice ID | 451791 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Other |
| Profit Type | FOR PROFIT |
| SSA county code | 910 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Cigarette smoking is associated with frequent substance use and poor behavioral and physical health in sexual and gender minority populations, according to Rutgers researchers.
The majority of hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project improve surgical outcomes over time, and improvement continues with each year that hospitals participate in the program, according to a new study published online today in Annals of Surgery.
Grégoire Courtine doesn't hesitate to use the word "revolutionary" when describing the emerging field of optogenetics – a technology that uses pulses of light to control individual neural activity – and what it could mean for neuroscience. Courtine, director of the NeuroRestore research center (with neurosurgeon Jocelyne Bloch), is currently developing an optogenetic implant together with Stéphanie Lacour, who holds the Bertarelli Foundation Chair in Neuroprosthetic Technology.
In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.
› Verified 8 days ago
| NPI Number | 1396742805 |
| Organization Name | Covenant Hospice & Palliative Care, Lp |
| Address | 3221 Collinsworth St Fort Worth, Texas, 76107 |
| Phone Number | (817)735-8741 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Cigarette smoking is associated with frequent substance use and poor behavioral and physical health in sexual and gender minority populations, according to Rutgers researchers.
The majority of hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project improve surgical outcomes over time, and improvement continues with each year that hospitals participate in the program, according to a new study published online today in Annals of Surgery.
Grégoire Courtine doesn't hesitate to use the word "revolutionary" when describing the emerging field of optogenetics – a technology that uses pulses of light to control individual neural activity – and what it could mean for neuroscience. Courtine, director of the NeuroRestore research center (with neurosurgeon Jocelyne Bloch), is currently developing an optogenetic implant together with Stéphanie Lacour, who holds the Bertarelli Foundation Chair in Neuroprosthetic Technology.
In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.
› Verified 8 days ago
| NPI Number | 1417139619 |
| Organization Name | Covenant Hospice & Palliative Care Llc |
| Address | 2630 West Fwy Ste 130 Fort Worth, Texas, 76102 |
| Phone Number | (817)735-8741 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Cigarette smoking is associated with frequent substance use and poor behavioral and physical health in sexual and gender minority populations, according to Rutgers researchers.
The majority of hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project improve surgical outcomes over time, and improvement continues with each year that hospitals participate in the program, according to a new study published online today in Annals of Surgery.
Grégoire Courtine doesn't hesitate to use the word "revolutionary" when describing the emerging field of optogenetics – a technology that uses pulses of light to control individual neural activity – and what it could mean for neuroscience. Courtine, director of the NeuroRestore research center (with neurosurgeon Jocelyne Bloch), is currently developing an optogenetic implant together with Stéphanie Lacour, who holds the Bertarelli Foundation Chair in Neuroprosthetic Technology.
In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.
› Verified 8 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 94.8 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 88.5 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 79.2 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 75.2 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 83.3 | 97.3 |
| Patients who got timely treatment for shortness of breath | 95.2 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 94.8 | 93.3 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Cigarette smoking is associated with frequent substance use and poor behavioral and physical health in sexual and gender minority populations, according to Rutgers researchers.
The majority of hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project improve surgical outcomes over time, and improvement continues with each year that hospitals participate in the program, according to a new study published online today in Annals of Surgery.
Grégoire Courtine doesn't hesitate to use the word "revolutionary" when describing the emerging field of optogenetics – a technology that uses pulses of light to control individual neural activity – and what it could mean for neuroscience. Courtine, director of the NeuroRestore research center (with neurosurgeon Jocelyne Bloch), is currently developing an optogenetic implant together with Stéphanie Lacour, who holds the Bertarelli Foundation Chair in Neuroprosthetic Technology.
In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.
› Verified 8 days ago
| Home Health Aides | 7 |
| Counselors | 2 |
| Homemakers | 0.25 |
| Medical Social Workers | 1 |
| Physicians | 2 |
| Registered Nurses | 9 |
| Total Employees | 21.25 |
|---|
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Cigarette smoking is associated with frequent substance use and poor behavioral and physical health in sexual and gender minority populations, according to Rutgers researchers.
The majority of hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project improve surgical outcomes over time, and improvement continues with each year that hospitals participate in the program, according to a new study published online today in Annals of Surgery.
Grégoire Courtine doesn't hesitate to use the word "revolutionary" when describing the emerging field of optogenetics – a technology that uses pulses of light to control individual neural activity – and what it could mean for neuroscience. Courtine, director of the NeuroRestore research center (with neurosurgeon Jocelyne Bloch), is currently developing an optogenetic implant together with Stéphanie Lacour, who holds the Bertarelli Foundation Chair in Neuroprosthetic Technology.
In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.
› Verified 8 days ago
| Community Hospice Of Texas Location: 6100 Western Place Suite 105, Fort Worth, Texas, 76107 Phone: (972) 548-1600 |
| Vitas Healthcare Of Texas Lp Location: 6100 Western Place, Ste 800, Fort Worth, Texas, 76107 Phone: (972) 548-1600 |
| Kindred At Home-hospice Location: 2630 West Freeway Suite 102, Fort Worth, Texas, 76102 Phone: (972) 548-1600 |
| Universal Health Services Location: 1208 Country Club Lane Ste #c, Fort Worth, Texas, 76112 Phone: (972) 548-1600 |